

2010

Ultrasensitive detection of antibodies using a new Tus-Ter-lock immunoPCR system

Isabelle Morin
James Cook University

Nicholas E. Dixon
University of Wollongong, nickd@uow.edu.au

Patrick M. Schaeffer
James Cook University

Follow this and additional works at: <https://ro.uow.edu.au/scipapers>



Part of the [Life Sciences Commons](#), [Physical Sciences and Mathematics Commons](#), and the [Social and Behavioral Sciences Commons](#)

Recommended Citation

Morin, Isabelle; Dixon, Nicholas E.; and Schaeffer, Patrick M.: Ultrasensitive detection of antibodies using a new Tus-Ter-lock immunoPCR system 2010, 1173-1175.
<https://ro.uow.edu.au/scipapers/490>

Ultrasensitive detection of antibodies using a new Tus-Ter-lock immunoPCR system

Abstract

A system consisting of a protein LG coated surface for the capture of mammalian antibodies (target), and an antigen fused to Tus and stoichiometrically linked to a DNA template via the Tus-Ter-lock sequence allowed the ultrasensitive detection of 5.5 attomol of target by real-time immunoPCR in complex media.
© The Royal Society of Chemistry 2010.

Keywords

ter, system, tus, immunopcr, antibodies, detection, ultrasensitive, lock, CMMB

Disciplines

Life Sciences | Physical Sciences and Mathematics | Social and Behavioral Sciences

Publication Details

Morin, I., Dixon, N. E. & Schaeffer, P. M. (2010). Ultrasensitive detection of antibodies using a new Tus-Ter-lock immunoPCR system. *Molecular BioSystems*, 6 (7), 1173-1175.

Ultrasensitive detection of antibodies using a new Tus–Ter-lock immunoPCR system†

Isabelle Morin,^a Nicholas E. Dixon^b and Patrick M. Schaeffer^{*a}

Received 1st February 2010, Accepted 26th February 2010

First published as an Advance Article on the web 8th March 2010

DOI: 10.1039/c002163f

A system consisting of a protein LG coated surface for the capture of mammalian antibodies (target), and an antigen fused to Tus and stoichiometrically linked to a DNA template *via* the Tus–Ter-lock sequence allowed the ultrasensitive detection of 5.5 attomol of target by real-time immunoPCR in complex media.

The early detection of life threatening diseases is essential for effective treatment and control of pandemics. Currently, the enzyme linked immunosorbent assay (ELISA) is still the gold standard for most immunodiagnostic methods.^{1,2} In immunoPCR (IPCR), the enzyme linked to the detection antibody (Ab) is replaced by a DNA template that can be amplified by PCR and visualised using an agarose gel.³ More recently, the use of quantitative real-time (rt) PCR has dramatically improved sensitivity and reproducibility, and so rt-IPCR has now been used to reliably detect a wide range of antigens such as tumour markers,^{4,5} viruses,⁶ prions⁷ and toxins.⁸ However, it has rarely been used to count antibody molecules in complex media.^{9,10} In a typical rt-IPCR setup for quantification of Abs (Fig. 1A), specific Abs bind to immobilised antigens and are detected by a secondary Ab–DNA conjugate.

The rt-IPCR method relies on the challenging synthesis of protein–DNA conjugates. Most commonly, a biotinylated DNA is linked to biotinylated Abs *via* a streptavidin bridge.^{6,11} While the biotin–streptavidin complex is strong ($K_d \approx 4 \times 10^{-14}$ M),¹² the resulting DNA–Ab conjugates are heterogeneous because streptavidin is tetrameric, affecting batch to batch reproducibility of the rt-IPCR. Moreover, this procedure requires multiple assembly and wash steps, and is expensive due to the high cost of reagents. DNA can also be covalently bound to Abs using bifunctional crosslinking agents or native chemical ligation.^{5,13} The latter covalently links the DNA site-specifically and with controlled stoichiometry, resulting in homogenous conjugates. However, all conjugation steps are complex, time-consuming and consequently preclude this technique from routine use in clinical settings.^{13,14} In addition, the non-specific binding of human anti-IgG has been shown to affect the sensitivity of IPCR dedicated to measure




Fig. 1 A. Schematic representation of an rt-IPCR setup for the detection of a specific antibody (Ab).⁹ B. Schematic representation of the TT-lock based rt-IPCR setup for the detection of Abs. The target Ab contained in a sample is mixed with Tus–antitarget and the complex is captured by the protein LG coated surface. TT-lock extended DNA template (TT-lock–T) binds to the Tus domain and is further quantified by rt-PCR. C. TT-lock based rt-IPCR setup used for validation and for the competitive format. Biotinylated anti-GFP (Bio-anti-GFP) Abs are mixed with Tus–GFP and the complex is captured by the streptavidin-coated surface. TT-lock–T binds to the Tus domain and is further quantified by rt-PCR.

Abs, compromising the advantages gained by PCR amplification compared to ELISA.⁹ Consequently, a new stratagem is needed to develop a powerful diagnostic tool dedicated to the accurate quantification of Abs in a complex biological sample.

Tus is a monomeric replication terminator protein that binds tightly to short DNA sequences called *Ter*, present in the *E. coli* chromosome. The Tus–*Ter*-lock (TT-lock) sequence is a partially forked ds*Ter* DNA oligonucleotide that makes an extremely stable interaction with Tus.¹⁵ In recent work, Tus has been successfully used as a fusion tag to covalently link a modified TT-lock sequence to GFP.¹⁶ Here, we use the TT-lock to stoichiometrically and site-specifically link a DNA template with an antigen or epitope for the production of an antitarget–DNA conjugate to be used as a sensitive detection device dedicated to quantify specific Abs. In this new approach, protein LG coated wells are used to immobilise antibodies present in a sample since protein LG binds strongly

^a Comparative Genomics Centre, School of Pharmacy & Molecular Sciences, DB 21, James Cook Drive, James Cook University, Townsville, QLD 4811, Australia.

E-mail: Patrick.Schaeffer@jcu.edu.au; Fax: +61 (0)7 47816078; Tel: +61 (0)7 47814448

^b School of Chemistry, University of Wollongong, Wollongong, Australia

† Electronic supplementary information (ESI) available: Experimental details and supplementary figures. See DOI: 10.1039/c002163f




Fig. 3 Detection of Bio-anti-GFP and anti-HA antibodies using a protein LG coated surface in complex media. A. Tus-GFP (0.4 nM) was incubated with a range of concentrations of Bio-anti-GFP Abs (33 fM–0.3 nM) in LG-coated wells, either in blocking solution (pure condition) or in complete cell culture medium supplemented with 10% foetal calf serum. After washes, the TT-lock-T (50 pM) was added to the well. After further wash steps, rt-PCR was used to quantify the bound TT-lock-T. B. Tus-HA (0.4 nM) was incubated with a range of concentrations of anti-HA Abs (33 fM–0.3 nM) in LG-coated wells, either in blocking solution (pure condition) or in cell culture medium. All subsequent steps were as described for Tus-GFP. Each point is the average of triplicates.

The detection limit in both conditions was estimated to be 111 fM. A similar experiment was used also to measure anti-HA Abs, using Tus fused with the hemagglutinin A (HA) epitope (Tus-HA) as the detection device; 111 fM of anti-HA Abs (~150 kDa) could be accurately quantified, corresponding to 5.5 pg mL⁻¹, with a detection limit of 33 fM (Fig. 3B). In comparison,¹⁰ anti-E2 antibodies were previously detected by an ultrasensitive rt-PCR in cell culture medium at 120 pg mL⁻¹. This demonstrates the outstanding performance of our IPCR setup. It is interesting to note that when assays were carried out in one pot, the limit of detection increased by almost two orders of magnitude, which is still acceptable for many diagnostic applications with the advantage that assay time was nearly halved (data not shown).

The TT-lock-based rt-IPCR presented here has a wide linear dynamic range of four orders of magnitude. It does not require the use of streptavidin–biotin chemistry, which is known to result in non-specific binding. The technique requires reduced numbers of steps and incubation times. As a result, rt-IPCR data were obtained within 5 h, all steps included. In addition, the technique demonstrated a very high batch to batch

reproducibility as a direct result of the use of the monomeric TT-lock system for the production of homogeneous protein–DNA conjugates.

Although we have tested this new system with two specific Abs and demonstrated its robustness and reproducibility, there is still space for further developments. For instance, the antitarget–Tus reagent is currently expressed in *E. coli*, which does not support any posttranslational modifications. It is yet to be shown if Tus fusion proteins can be expressed in eukaryotic systems to produce posttranslationally modified antitarget fusion proteins, which would be very useful reagents. Additionally, although the TT-lock complex is extremely stable, it will still dissociate over time, limiting its use to monoplex rt-IPCR applications. We have previously shown that introduction of a 5-bromodeoxyuridine residue into the TT-lock enables simple production of irreversibly photocrosslinked Tus–DNA conjugates in high yields.¹⁶ This strategy could be used in our TT-lock based rt-IPCR to afford a route to multiplex rt-IPCR. Due to the simple methods for reagent preparation and its reproducibility, we expect TT-lock based rt-IPCR methods to become useful tools for a broad range of biomedical applications. We are currently developing other formats of this method for the detection of antigens using both monoplex and multiplex strategies.

This work was supported by a grant from the National Health and Medical Research Council (Australia).

Notes and references

- 1 E. Engvall and P. Perlmann, *Immunochemistry*, 1971, **8**, 871–874.
- 2 B. K. van Weemen, A. H. W. M. Schuurs, M. W. Oostermeijer and H. H. T. Raymakers, *FEBS Lett.*, 1974, **43**, 215–218.
- 3 T. Sano, C. L. Smith and C. R. Cantor, *Science*, 1992, **258**, 120–122.
- 4 K. Lind and M. Kubista, *J. Immunol. Methods*, 2005, **304**, 107–116.
- 5 I. Burbulis, K. Yamaguchi, R. Yu, O. Resnekov and R. Brent, *Nat. Methods*, 2007, **4**, 1011–1013.
- 6 J. Barletta, A. Bartolomeo and N. T. Constantine, *J. Virol. Methods*, 2009, **157**, 122–132.
- 7 J. M. Barletta, D. C. Edelman, W. E. Highsmith and N. T. Constantine, *J. Virol. Methods*, 2005, **127**, 154–164.
- 8 A. Fischer, C. von Eiff, T. Kuczius, K. Omoe, G. Peters and K. Becker, *J. Mol. Med.*, 2007, **85**, 461–469.
- 9 A. McKie, D. Samuel, B. Cohen and N. A. Saunders, *J. Immunol. Methods*, 2002, **261**, 167–175.
- 10 M. Adler, R. Wacker and C. M. Niemeyer, *Biochem. Biophys. Res. Commun.*, 2003, **308**, 240–250.
- 11 W. Zhang, M. Bielaszewska, M. Pulz, K. Becker, A. W. Friedrich, H. Karch and T. Kuczius, *J. Clin. Microbiol.*, 2008, **46**, 1292–1297.
- 12 N. M. Green, *Methods Enzymol.*, 1990, **184**, 51–67.
- 13 E. R. Hendrickson, T. M. Hatfield Truby, R. D. Joerger, W. R. Majarian and R. C. Ebersole, *Nucleic Acids Res.*, 1995, **23**, 522–529.
- 14 R. C. Allen, S. Rogelj, S. E. Cordova and T. L. Kieft, *J. Immunol. Methods*, 2006, **308**, 109–115.
- 15 M. D. Mulcair, P. M. Schaeffer, A. J. Oakley, H. F. Cross, C. Neylon, T. M. Hill and N. E. Dixon, *Cell (Cambridge, Mass.)*, 2006, **125**, 1309–1319.
- 16 D. B. Dahdah, I. Morin, M. J. J. Moreau, N. E. Dixon and P. M. Schaeffer, *Chem. Commun.*, 2009, 3050–3052.
- 17 B. M. Kihlberg, U. Sjöbring, W. Kastern and L. J. Björck, *J. Biol. Chem.*, 1992, **267**, 25583–25588.
- 18 B.-M. Kihlberg, A. G. Sjöholm, L. Björck and U. Sjöbring, *Eur. J. Biochem.*, 1996, **240**, 556–563.

